Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide

Enzalutamide is an androgen receptor (AR) inhibitor approved for therapy of metastatic castration resistant prostate cancer. However, clinical application revealed that 30 to 40% of patients acquire resistance after a short period of treatment. Currently, the molecular mechanisms underlying such res...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoefer, Julia, Akbor, Mohammady, Handle, Florian, Ofer, Philipp, Puhr, Martin, Parson, Walther, Culig, Zoran, Klocker, Helmut, Heidegger, Isabel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312348/
https://www.ncbi.nlm.nih.gov/pubmed/27486973
http://dx.doi.org/10.18632/oncotarget.10926

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312348/
https://www.ncbi.nlm.nih.gov/pubmed/27486973
http://dx.doi.org/10.18632/oncotarget.10926

Ejemplares similares